Pharma and biotechnology company Symbiotec Pharmalab is preparing to enter the primary market with a Rs. 1,757-cr. IPO, scheduled to open on August 24. The upcoming issue is among the larger offerings expected to reach investors later this month.
The company operates in pharmaceutical and biotechnology-related manufacturing, giving investors exposure to India’s growing healthcare and life-sciences sector. The IPO will be watched for its valuation, financial performance, use of proceeds and institutional demand once the issue opens.
